Fenofibrate ( DrugBank: Fenofibrate )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1
79	家族性高コレステロール血症（ホモ接合体）	1
93	原発性胆汁性胆管炎	8
94	原発性硬化性胆管炎	1
97	潰瘍性大腸炎	1
265	脂肪萎縮症	1

8. ハンチントン病

臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03515213 (ClinicalTrials.gov)	April 27, 2017	2/8/2017	Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease	A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofi ...	Huntington Disease	Drug: Fenofibrate;Drug: Placebo	University of California, Irvine	NULL	Active, not recruiting	18 Years	N/A	All	20	Phase 2	United States

First Previous1Next Last

79. 家族性高コレステロール血症（ホモ接合体）

臨床試験数 : 145 / 薬物数 : 114 - (DrugBank : 26) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 17

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03510715 (ClinicalTrials.gov)	August 31, 2018	18/4/2018	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hype ...	An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents Wi ...	Hypercholesterolemia	Drug: Alirocumab SAR236553 (REGN727);Drug: Rosuvastatin;Drug: Ezetimibe;Drug: Cholestyramine;Drug: N ...	Sanofi	Regeneron Pharmaceuticals	Completed	8 Years	17 Years	All	18	Phase 3	Brazil;Canada;Denmark;Mexico;Netherlands;Russian Federation;Slovenia;Spain;Taiwan;Turkey;Austria;Fra ...

First Previous1Next Last

93. 原発性胆汁性胆管炎

臨床試験数 : 298 / 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05751967 (ClinicalTrials.gov)	February 22, 2023	13/12/2022	Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis	A Prospective, Multi-center, Randomized, Double-blind, Placebo-controlled Study: FenofibrateCombined ...	Primary Biliary Cholangitis	Drug: Placebo Combined With Ursodeoxycholic Acid;Drug: FenofibrateCombined With Ursodeoxycholic Acid ...	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	75 Years	All	150	Phase 3	China
2	NCT05749822 (ClinicalTrials.gov)	February 17, 2023	29/12/2022	Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis	FenofibrateCombined With Ursodeoxycholic Acid in Compensated Cirrhosis Patients With Primary Biliary ...	Primary Biliary Cholangitis	Drug: Fenofibrate 200mg;Drug: Placebo;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	75 Years	All	104	Phase 2/Phase 3	China
3	ChiCTR1800020160	2018-12-20	2018-12-18	Clinical research for fenofibrate in the treatment of refractory primary biliary cirrhosis	Clinical research for fenofibrate in the treatment of refractory primary biliary cirrhosis	Primary Biliary Cirrhosis	1:Fenofibrate+UDCA;2:UDCA;	Peking Union Medical College Hosipital	NULL	Recruiting	18	65	Both	1:20;2:20;		China
4	NCT02823353 (ClinicalTrials.gov)	April 8, 2016	28/1/2016	Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis	Fenofibratein Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Contr ...	Primary Biliary Cirrhosis	Drug: Fenofibrate;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Completed	18 Years	70 Years	All	117	Phase 3	China
5	NCT02823366 (ClinicalTrials.gov)	January 2016	28/1/2016	Fenofibratefor Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxych ...		Primary Biliary Cirrhosis	Drug: Fenofibrate;Drug: UDCA	Xijing Hospital of Digestive Diseases	NULL	Recruiting	18 Years	70 Years	All	104	Phase 3	China
6	NCT02965911 (ClinicalTrials.gov)	January 2016	15/11/2016	Efficacy and Safety of FenofibrateCombined With UDCA in PBC Patients With an Incomplete Biochemical ...	A Randomized Controlled Clinical Trial on the Efficacy and Safety of FenofibrateCombined With Ursode ...	Primary Biliary Cirrhosis	Drug: Fenofibrate;Drug: UDCA	Beijing 302 Hospital	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 1/Phase 2	China
7	NCT01141296 (ClinicalTrials.gov)	April 2011	8/6/2010	Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis	Randomized Controlled Study of Fenofibratein Combination With Ursodeoxycholic Acid in Primary Biliar ...	Primary Biliary Cirrhosis	Drug: fenofibrate;Drug: placebo	University of Miami	Mayo Clinic	Withdrawn	21 Years	75 Years	Both	0	Phase 2	United States
8	NCT00575042 (ClinicalTrials.gov)	August 2007	13/12/2007	Use of Fenofibrate for Primary Biliary Cirrhosis	Pilot Study of Fenofibrate for Primary Biliary Cirrhosis	Primary Biliary Cirrhosis	Drug: Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)	University of Florida	The PBCers Organization;Shionogi Inc.	Completed	21 Years	75 Years	All	20	Phase 2	United States

First Previous1Next Last

先頭へ

94. 原発性硬化性胆管炎

臨床試験数 : 148 / 薬物数 : 118 - (DrugBank : 39) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 141

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01142323 (ClinicalTrials.gov)	October 2010	10/6/2010	Pilot Study of Fenofibrate for PSC	Pilot Study of Fenofibrate in Primary Sclerosing Cholangitis	Primary Sclerosing Cholangitis	Drug: fenofibrate	University of Miami	University of Florida	Terminated	18 Years	75 Years	All	8	Phase 1/Phase 2	United States

First Previous1Next Last

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05753267 (ClinicalTrials.gov)	February 28, 2023	22/2/2023	Fenofibrate in Ulcerative Colitis	Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative Colitis	Inflammatory Bowel Diseases	Drug: Mesalamine;Drug: Fenofibrate 160mg	Tanta University	Eman Ibrahim Elberri, Faculty of Pharmacy, Tanta University;Hend El-Said Abo Mansour, Faculty of Pha ...	Recruiting	18 Years	75 Years	All	60	Phase 2/Phase 3	Egypt

First Previous1Next Last

265. 脂肪萎縮症

臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00006412 (ClinicalTrials.gov)	October 25, 2000	13/10/2000	Safety and Effectiveness of Fenofibrateand Pravastatin in HIV-Positive Patients With Abnormal Blood ...	A Prospective, Multicenter, Randomized Trial Comparing the Efficacy and Safety of FenofibrateVersus ...	HIV Infections;Lipodystrophy	Drug: Pravastatin sodium;Drug: Fenofibrate	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Completed	18 Years	N/A	All	630	Phase 3	United States;Puerto Rico

First Previous1Next Last

先頭へ